Innoviz Technologies reports today with a rare combination of signals: nearly 10% of the float sold short, borrow availability close to fully exhausted, and a stock that has rallied more than 35% in a month — all colliding on the same day as the earnings print.
The short-side pressure here is genuine. Short interest has held stubbornly near 10% of free float for weeks, and the lending market has been almost entirely locked up — availability has been at or near zero for most of the past six weeks, with the 52-week peak utilisation hitting 100% on multiple occasions. That kind of persistent tightness, combined with a days-to-cover of 8.3, means any rush to cover would have few willing sellers of borrow to accommodate it. Cost to borrow has eased modestly to around 2.5% from highs above 3.4% in early April, but remains elevated for a sub-$1 stock. The ORTEX short score of 76.5 ranks this stock in the first percentile of the universe on both short score and days-to-cover — squarely in the cohort of names where short positioning is most extreme.
Against that, options traders are painting a completely different picture. The put/call ratio has dropped to a near-record low of 0.09 — brushing against its 52-week floor of 0.076 — and is essentially flat to its 20-day average. There is no options-market bid for downside protection heading into the print; call positioning overwhelmingly dominates. That bullish options skew aligns with a stock that has gained 22% over the past week and 35% over the past month, recovering sharply from earlier lows. The contrast between extreme short positioning and near-record bullish options sentiment is the central tension heading into the print.
On the analyst side, the picture is divided. Goldman Sachs downgraded to Neutral in mid-April and cut its target to $0.75 — a level the stock has since blown past, now trading at $0.92. Amerx initiated coverage this week at Buy with a $2.77 target, reflecting the more optimistic view that Innoviz can scale toward a $101 million revenue run-rate by FY26, with vehicle production potentially beginning in 2027 as a step-change catalyst. The bear case centres on the well-documented risks of LiDAR adoption timelines slipping, SPAC-vintage financing challenges, and competition compressing average selling prices before the company reaches scale. State Street added 2.3 million shares through April, and Citigroup added 1.5 million through December — modest institutional accumulation that suggests some confidence in the longer-term story, even as the Goldman downgrade remains a live overhang.
The earnings print is therefore less a test of whether Innoviz is on track and more a test of whether the progress toward 2027 production milestones is intact — and whether that justifies a stock trading at nearly double the Street's most bearish price target.
See the live data behind this article on ORTEX.
Open INVZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
